ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.

ProKidney Corp.

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s sh...

Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)

Prokidney Corp. (($PROK)) announced an update on their ongoing clinical study. Prokidney Corp. is currently conducting a clinical study titled ‘A P...

Market Cap	$685.90M	P/E Ratio	N/A
52W High	$7.13	52W Low	$0.46
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	25.9%
Overall Score	25	Value Score	40
Quality Score	--	Technical Score	10

EPS Current Est	$-0.65	EPS Next Est	$-0.67
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PROK	$2.19	+4.78%	1.53M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PROK	$2.19	+4.8%	1.53M
3
4
5
6

PROK

PROK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ProKidney Corp. Data in Excel

Get ProKidney Corp. Data in Excel